FDA OKs less frequent Tecvayli dosing for treatment responders
The U.S. Food and Drug Administration (FDA) has cleared…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Elrexfio now approved in Canada as recurring myeloma treatment
Health Canada has granted conditional approval to Pfizer’s…
Blenrep delays disease progression by nearly 3X versus Darzalex
GlaxoSmithKline (GSK)’s Blenrep (belantamab mafodotin) significantly reduced by…
Regeneron seeking approval of linvoseltamab for RRMM in US, EU
The European Medicines Agency has agreed to review Regeneron…
Abecma wins CHMP’s thumbs up for use in earlier treatment lines
Bristol Myers Squibb has received a positive opinion…
Treating hepatitis may improve patient outcomes in myeloma
A dysregulated immune response against viruses that cause hepatitis…
